DK2641596T3 - Anvendelse af 1,3-diphenylprop-2-en-1-on-derivater til behandling af leverlidelser - Google Patents
Anvendelse af 1,3-diphenylprop-2-en-1-on-derivater til behandling af leverlidelser Download PDFInfo
- Publication number
- DK2641596T3 DK2641596T3 DK13170128.6T DK13170128T DK2641596T3 DK 2641596 T3 DK2641596 T3 DK 2641596T3 DK 13170128 T DK13170128 T DK 13170128T DK 2641596 T3 DK2641596 T3 DK 2641596T3
- Authority
- DK
- Denmark
- Prior art keywords
- group
- compound
- liver
- alkyl group
- substituted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
- C07C49/782—Ketones containing a keto group bound to a six-membered aromatic ring polycyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Child & Adolescent Psychology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
Claims (12)
- 1. Forbindelse af generel formel (I)i hvilken: XI repræsenterer en halogen-, en RI-, eller Gl-Rl-gruppe; A repræsenterer en CH=CH- eller en CH2-CH2-gruppe; X2 repræsentereren G2-R2-gruppe; GI og G2, identiske eller forskellige, repræsenterer et atom af oxygen eller svovl; RI repræsenterer et hydrogenatom, en ikke-substitueret alkylgruppe, en arylgruppe eller en alkylgruppe, der er substitueret af et eller flere halogenatomer, en alkoxy- eller en alkylthiogruppe, cykloalkylgrupper, cykloalkylthiogrupper eller heterocykliske grupper; R2 repræsenterer en alkylgruppe substitueret af mindst en -COOR3-gruppe, hvor R3 repræsenterer et hydrogenatom, eller en alkylgruppe, der er substitueret eller ikke af et eller flere halogenatomer, cykloalkylgrupper, eller heterocykliske grupper. R4 og R5, identiske eller forskellige, repræsenterer en alkylgruppe, der er substitueret eller ikke af et eller flere halogenatomer, cykloalkylgrupper, heterocykliske grupper; til anvendelse i en fremgangsmåde til behandlingen afen leverlidelse valgt fra gruppen bestående af levercirrose, alkoholrelaterede leversygdomme, immunmedierede leversygdomme.
- 2. Forbindelsen ifølge krav 1 til anvendelse ifølge krav 1, hvor forbindelsen er af generel formel (I) i hvilken: XI repræsenterer en halogen-, en RI-, eller en Gl-Rl-gruppe; A repræsenterer en CH=CH-gruppe; X2 repræsentereren G2-R2-gruppe; GI og G2, identiske eller forskellige, repræsenterer et atom af oxygen eller svovl; RI repræsenterer en alkyl- eller cykloalkylgruppe med fra en til syv carbonatomer, i særdeleshed, hvor alkyl- eller cykloalkylgruppen er substitueret eller ikke af et eller flere halogenatomer; R2 repræsenterer en alkylgruppe substitueret af en -COOR3-gruppe, hvor R3 repræsenterer et hydrogenatom eller en alkylgruppe med fra en til fire carbonatomer. R4 og R5 repræsenterer en alkylgruppe med fra en til fire carbonatomer.
- 3. Forbindelsen ifølge krav 1 til anvendelse ifølge krav 1, hvor forbindelsen er af generel formel (I) i hvilken: XI repræsenterer en RI- eller Gl-Rl-gruppe; A repræsenterer en CH2-CH2-gruppe; X2 repræsentereren G2-R2-gruppe; GI repræsenterer et atom af oxygen eller svovl og G2 repræsenterer et atom af oxygen; RI repræsenterer en alkyl- eller cykloalkylgruppe med fra en til syv carbonatomer; R2 repræsenterer en alkylgruppe substitueret af mindst en -COOR3-gruppe, hvor R3 repræsenterer et hydrogenatom eller en alkylgruppe med fra en til fire carbonatomer; R4 og R5 repræsenterer en alkylgruppe med fra en til fire carbonatomer.
- 4. Forbindelsen ifølge krav 1 til anvendelse ifølge krav 1, hvor forbindelsen er af generel formel (I) i hvilken: XI repræsenterer et halogenatom eller en RI- eller Gl-Rl-gruppe; A repræsenterer en CH2-CH2-gruppe; X2 repræsentereren G2-R2-gruppe; GI repræsenterer et atom af oxygen eller svovl og G2 repræsenterer et atom af oxygen; RI repræsenterer en alkyl- eller cykloalkylgruppe, der er substitueret af et eller flere halogenatomer; R2 repræsenterer en alkylgruppe substitueret eller ikke af et eller flere halogenatomer og substitueret af mindst en -COOR3-gruppe, hvor R3 repræsenterer et hydrogenatom eller en alkylgruppe med fra en til fire carbonatomer. R4 og R5 repræsenterer en alkylgruppe med fra en til fire carbonatomer.
- 5. Forbindelsen ifølge et hvilket som helst af de foregående krav til anvendelse ifølge krav 1, hvor G2 er et oxygenatom og R2 er en alkylgruppe substitueret af en -COOR3-gruppe, hvor R3 repræsenterer et hydrogenatom eller en ikke-substitueret lineær eller forgrenet alkylgruppe med fra en til fire carbonatomer.
- 6. Forbindelsen ifølge et hvilket som helst af de foregående krav til anvendelse ifølge krav 1, hvor XI er en alkylthiogruppe, der omfatter en alkylgruppe, der er lineær eller forgrenet, med fra en til syv carbonatomer, der er substitueret eller ikke af et eller flere halogenatomer.
- 7. Forbindelsen ifølge et hvilket som helst af de foregående krav til anvendelse ifølge krav 1, hvor nævnte forbindelse er valgt fra gruppen bestående af l-[4-methylthiophenyl]-3-[3,5-dimethyl-4-carboxydimethylmethyloxyphenyl]prop-2-en-l-on, l-[4-methylthiophenyl]-3-[3,5-dimethyl-4-isopropyloxy carbonyldimethylmethyloxyphenyl]prop-2-en-l -on, l-[4-methylthiophenyl]-3-[3,5-dimethyl-4-tertbutyloxycarbonyldimethylmethyloxyphenyl] prop-2-en-l-on, l-[4-trifluormethylphenyl]-3-[3,5-dimethyl-4-tertbutyloxycarbonyl dimethylmethyloxyphenyl]prop-2-en-l-on, l-[4-trifluormethylphenyl]-3-[3,5-dimethyl-4-carboxydimethylmethyloxyphenyl]prop-2-en-l-on, l-[4-trifluormethyl oxyphenyl]-3-[3,5-dimethyl-4-tertbutyloxycarbonyldimethylmethyloxy phenyl] prop-2-en-l-on, l-[4-trifluormethyloxyphenyl]-3-[3,5-dimethyl-4- carboxydimethylmethyloxyphenyl]prop-2-en-l-on, 2-[2,6-dimethyl-4-[3-[4-(methylthio)phenyl]-3-oxo-propyl] phenoxy]-2-methylpropionsyre, og 2-[2,6-dimethyl-4-[3-[4-(methylthio)phenyl]-3-oxopropyl]phenoxy]-2-methyl-propionsyre-isopropylester.
- 8. Forbindelsen ifølge et hvilket som helst af de foregående krav til anvendelse ifølge krav 1, hvor forbindelsen er administreret i kombination med metformin, insulin, thiazolidinedioner, glitazoner, eller statiner.
- 9. Forbindelsen ifølge et hvilket som helst af kravene 1 til 8 til anvendelse ifølge krav 1, hvor sygdommen er levercirrose.
- 10. Farmaceutisk sammensætning omfattende en forbindelse af generel formel (I) som defineret i et hvilket som helst af kravene 1 til 9, til anvendelse i en fremgangsmåde til behandlingen af en leverlidelse valgt fra gruppen bestående af levercirrose alkoholrelaterede leversygdomme, immunmedierede leversygdomme.
- 11. Sammensætningen ifølge krav 10 til anvendelse ifølge krav 10, hvor leversygdommen er levercirrose.
- 12. Den farmaceutiske sammensætning ifølge krav 10 til anvendelse ifølge krav 10, hvor nævnte sammensætning er formuleret i formen af injicerbare suspensioner, geler, olier, piller, suppositorier, pulvere, gelkapsler, kapsler, aerosoler eller ved hjælp af galeniske former eller indretninger, som sikrer en forlænget og/eller langsom frigivelse.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09306146 | 2009-11-26 | ||
| EP10787363.0A EP2504005B1 (en) | 2009-11-26 | 2010-11-26 | Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2641596T3 true DK2641596T3 (da) | 2018-08-06 |
Family
ID=43587223
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK10787363.0T DK2504005T3 (da) | 2009-11-26 | 2010-11-26 | Anvendelse af 1,3-diphenylprop-2-en-1-on-derivater til behandling af lever-sygdomme |
| DK13170128.6T DK2641596T3 (da) | 2009-11-26 | 2010-11-26 | Anvendelse af 1,3-diphenylprop-2-en-1-on-derivater til behandling af leverlidelser |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK10787363.0T DK2504005T3 (da) | 2009-11-26 | 2010-11-26 | Anvendelse af 1,3-diphenylprop-2-en-1-on-derivater til behandling af lever-sygdomme |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US8772342B2 (da) |
| EP (2) | EP2641596B1 (da) |
| JP (4) | JP5833016B2 (da) |
| KR (2) | KR101962209B1 (da) |
| CN (2) | CN104434891B (da) |
| AU (1) | AU2010323066B2 (da) |
| BR (1) | BR112012012815B8 (da) |
| CA (1) | CA2781451C (da) |
| CY (2) | CY1116548T1 (da) |
| DK (2) | DK2504005T3 (da) |
| EA (1) | EA020849B1 (da) |
| ES (2) | ES2441665T3 (da) |
| HK (1) | HK1175716A1 (da) |
| HU (1) | HUE039731T2 (da) |
| IL (2) | IL219914A (da) |
| LT (1) | LT2641596T (da) |
| MX (1) | MX2012006062A (da) |
| NZ (1) | NZ600439A (da) |
| PL (2) | PL2641596T3 (da) |
| PT (2) | PT2504005E (da) |
| SI (2) | SI2641596T1 (da) |
| TR (1) | TR201810393T4 (da) |
| WO (1) | WO2011064350A1 (da) |
| ZA (1) | ZA201204658B (da) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9221751B2 (en) | 2009-11-26 | 2015-12-29 | Genfit | Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders |
| ES2441665T3 (es) * | 2009-11-26 | 2014-02-05 | Genfit | Utilización de derivados de 1,3-difenilprop-2-en-1-ona para tratar trastornos hepáticos |
| US10722575B2 (en) | 2009-11-26 | 2020-07-28 | Genfit | Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders |
| CA2825456C (en) | 2011-01-31 | 2016-01-05 | Cadila Healthcare Limited | Treatment for lipodystrophy |
| PL2948137T3 (pl) * | 2013-01-18 | 2019-02-28 | Genfit | Sposoby leczenia zwłóknienia i nowotworów |
| WO2014174524A1 (en) | 2013-04-22 | 2014-10-30 | Cadila Healthcare Limited | A novel composition for nonalcoholic fatty liver disease (nafld) |
| MX2015016403A (es) | 2013-05-30 | 2016-04-11 | Cadila Healthcare Ltd | Proceso para la preparacion de pirroles que tienen actividad hipolipidemica e hipocolesterolemica. |
| TW201636015A (zh) | 2013-07-05 | 2016-10-16 | 卡地拉保健有限公司 | 協同性組成物 |
| IN2013MU02470A (da) | 2013-07-25 | 2015-06-26 | Cadila Healthcare Ltd | |
| WO2015033357A2 (en) | 2013-09-06 | 2015-03-12 | Cadila Healthcare Limited | An improved process for the preparation of pyrrole derivatives |
| AU2015273454B2 (en) | 2014-06-13 | 2019-09-05 | Inventiva | PPAR compounds for use in the treatment of fibrotic diseases. |
| AU2016215179B2 (en) * | 2015-02-06 | 2021-02-25 | Intercept Pharmaceuticals, Inc. | Pharmaceutical compositions for combination therapy |
| EA201890724A1 (ru) * | 2015-09-14 | 2018-10-31 | Женфит | Способы диагностики и оценки неалкогольного стеатогепатита |
| WO2017064635A2 (en) | 2015-10-14 | 2017-04-20 | Cadila Healthcare Limited | Pyrrole compound, compositions and process for preparation thereof |
| EP3416629A4 (en) * | 2016-02-16 | 2019-08-07 | CoNCERT Pharmaceuticals, Inc. | DEUTERATED GFT-505 |
| US11331292B2 (en) | 2016-03-31 | 2022-05-17 | Genfit | Methods of treatment of cholestatic diseases |
| US20220133666A1 (en) | 2016-03-31 | 2022-05-05 | Genfit | Methods of treatment of cholestatic diseases |
| BR112018069023A2 (pt) * | 2016-03-31 | 2019-01-29 | Genfit | métodos de tratamento de doenças colestáticas |
| FR3056909B1 (fr) * | 2016-09-30 | 2019-04-19 | Nashpharm | Composition comprenant au moins un sel pharmaceutiquement acceptable d'elafibranor soluble en milieux aqueux presentant une absorption intestinale amelioree |
| FR3056908B1 (fr) * | 2016-09-30 | 2019-04-19 | Nashpharm | Sel de metformine et d'elafibranor presentant une activite duale pour le traitement de l'obesite associee a la steato-hepatite non alcoolique (nash) et a l'hypertriglyceridemie |
| US20180243263A1 (en) | 2016-12-09 | 2018-08-30 | Cadila Healthcare Ltd. | Treatment for primary biliary cholangitis |
| WO2018133705A1 (zh) * | 2017-01-22 | 2018-07-26 | 苏州科睿思制药有限公司 | Gft-505的晶型及其制备方法和用途 |
| WO2018154081A1 (en) * | 2017-02-24 | 2018-08-30 | Genfit | Pharmaceutical compositions for combination therapy |
| WO2018193007A1 (en) * | 2017-04-18 | 2018-10-25 | Genfit | Combination comprising a ppar agonist such as elafibranor and an acetyl-coa carboxylase (acc) inhibitor |
| CN111148742B (zh) | 2017-11-30 | 2021-11-16 | 四川科伦博泰生物医药股份有限公司 | 芳香族化合物及其药物组合物和用途 |
| CN112513003A (zh) | 2018-08-03 | 2021-03-16 | 基恩菲特公司 | 伊拉非诺盐 |
| US20210380521A1 (en) * | 2018-10-11 | 2021-12-09 | Basf As | Aromatic compounds and pharmaceutical uses thereof |
| RU2702003C1 (ru) * | 2019-03-18 | 2019-10-03 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Санкт-Петербургский государственный химико-фармацевтический университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО СПХФУ Минздрава России) | Антистеатозное средство |
| CN113677336B (zh) * | 2019-04-10 | 2024-04-30 | 基恩菲特公司 | 包含式(i)化合物和glp-1受体激动剂的组合疗法 |
| CN110143902B (zh) * | 2019-06-12 | 2021-06-04 | 天津科技大学 | 含硒查尔酮衍生物Compound 1和合成方法及在抗非酒精性脂肪肝炎药物中的应用 |
| CN110143890B (zh) * | 2019-06-12 | 2020-12-22 | 天津科技大学 | 一种查尔酮衍生物和合成方法及其在制备抗非酒精性脂肪肝炎药物中的应用 |
| BR112022015807A2 (pt) | 2020-02-10 | 2023-03-14 | Genfit | Polimorfos de elafibranor |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH04202129A (ja) | 1990-11-30 | 1992-07-22 | Terumo Corp | 肝障害治療薬 |
| AU693110B2 (en) * | 1993-08-19 | 1998-06-25 | Warner-Lambert Company | Substituted 2(5H)furanone, 2(5H)thiophenone and 2(5H)pyrrolone derivatives, their preparation and their use as endothelin antagonists |
| CA2395191A1 (en) | 1999-12-23 | 2001-06-28 | Tedman Ehlers | Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states |
| IL153565A0 (en) | 2000-06-20 | 2003-07-06 | Atherogenics Inc | 1,3-bis-(substituted-phenyl)-2-propen-1-ones and their use to treat vcam-1 mediated disorders |
| KR100567125B1 (ko) | 2001-11-01 | 2006-03-31 | 주식회사 안지오랩 | 칼콘 또는 이의 유도체를 함유하는 매트릭스메탈로프로테아제 활성 억제용 약학 조성물 |
| FR2841784B1 (fr) * | 2002-07-08 | 2007-03-02 | Composition a base de derives de 1,3-diphenylprop-2en-1-one substitues, preparation et utilisations | |
| FR2841900B1 (fr) | 2002-07-08 | 2007-03-02 | Genfit S A | Nouveaux derives de 1,3-diphenylprop-2-en-1-one substitues, preparation et utilisations |
| FR2857361B1 (fr) | 2003-07-08 | 2005-09-09 | Genfit S A | PREPARATION DE DERIVES DE 1,3-DIPHENYPROP-2-¼n-1-one |
| US7547729B2 (en) | 2004-01-08 | 2009-06-16 | Genfit | 1,3-diphenylprop-2-en-1-one derivative compounds, preparation method thereof and uses of same |
| JP4689331B2 (ja) | 2005-04-19 | 2011-05-25 | 三菱電機株式会社 | 撮像装置 |
| FR2902789A1 (fr) * | 2006-06-21 | 2007-12-28 | Genfit Sa | Derives de 1,3-diphenylpropane substitues, preparations et utilisations |
| DE102006062264A1 (de) * | 2006-12-22 | 2008-06-26 | Joh. Barth & Sohn Gmbh & Co. Kg | Verwendung von Xanthohumol zur Vorbeugung und/oder Bekämpfung von Lebererkrankungen |
| ES2441665T3 (es) | 2009-11-26 | 2014-02-05 | Genfit | Utilización de derivados de 1,3-difenilprop-2-en-1-ona para tratar trastornos hepáticos |
-
2010
- 2010-11-26 ES ES10787363.0T patent/ES2441665T3/es active Active
- 2010-11-26 CN CN201410458131.4A patent/CN104434891B/zh active Active
- 2010-11-26 NZ NZ600439A patent/NZ600439A/en unknown
- 2010-11-26 DK DK10787363.0T patent/DK2504005T3/da active
- 2010-11-26 US US13/511,170 patent/US8772342B2/en active Active
- 2010-11-26 HU HUE13170128A patent/HUE039731T2/hu unknown
- 2010-11-26 EP EP13170128.6A patent/EP2641596B1/en active Active
- 2010-11-26 KR KR1020187008005A patent/KR101962209B1/ko active IP Right Grant
- 2010-11-26 MX MX2012006062A patent/MX2012006062A/es active IP Right Grant
- 2010-11-26 PT PT107873630T patent/PT2504005E/pt unknown
- 2010-11-26 CA CA2781451A patent/CA2781451C/en active Active
- 2010-11-26 PL PL13170128T patent/PL2641596T3/pl unknown
- 2010-11-26 AU AU2010323066A patent/AU2010323066B2/en active Active
- 2010-11-26 JP JP2012540447A patent/JP5833016B2/ja active Active
- 2010-11-26 EA EA201290389A patent/EA020849B1/ru not_active IP Right Cessation
- 2010-11-26 ES ES13170128.6T patent/ES2681794T3/es active Active
- 2010-11-26 CN CN201080053762.8A patent/CN102647982B/zh active Active
- 2010-11-26 TR TR2018/10393T patent/TR201810393T4/tr unknown
- 2010-11-26 BR BR112012012815A patent/BR112012012815B8/pt active IP Right Grant
- 2010-11-26 SI SI201031723T patent/SI2641596T1/sl unknown
- 2010-11-26 KR KR1020127016566A patent/KR101865677B1/ko active IP Right Grant
- 2010-11-26 LT LTEP13170128.6T patent/LT2641596T/lt unknown
- 2010-11-26 PT PT131701286T patent/PT2641596T/pt unknown
- 2010-11-26 DK DK13170128.6T patent/DK2641596T3/da active
- 2010-11-26 EP EP10787363.0A patent/EP2504005B1/en active Active
- 2010-11-26 SI SI201030472T patent/SI2504005T1/sl unknown
- 2010-11-26 PL PL10787363T patent/PL2504005T3/pl unknown
- 2010-11-26 WO PCT/EP2010/068346 patent/WO2011064350A1/en active Application Filing
-
2012
- 2012-05-21 IL IL219914A patent/IL219914A/en active IP Right Grant
- 2012-06-22 ZA ZA2012/04658A patent/ZA201204658B/en unknown
-
2013
- 2013-03-13 HK HK13103133.7A patent/HK1175716A1/xx unknown
-
2014
- 2014-01-07 CY CY20141100010T patent/CY1116548T1/el unknown
- 2014-05-28 US US14/288,482 patent/US8895619B2/en active Active
-
2015
- 2015-09-21 IL IL241791A patent/IL241791A0/en active IP Right Grant
- 2015-10-28 JP JP2015212306A patent/JP2016074670A/ja active Pending
-
2017
- 2017-12-14 JP JP2017239237A patent/JP6594400B2/ja active Active
-
2018
- 2018-07-20 CY CY20181100759T patent/CY1120444T1/el unknown
-
2019
- 2019-09-24 JP JP2019173268A patent/JP2020073468A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2641596T3 (da) | Anvendelse af 1,3-diphenylprop-2-en-1-on-derivater til behandling af leverlidelser | |
| US10350181B2 (en) | Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders | |
| AU2018223146B2 (en) | Combination of a PPAR agonist with a FXR agonist | |
| US20200384105A1 (en) | Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders |